These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 18574491

  • 1. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 2. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM.
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [Abstract] [Full Text] [Related]

  • 3. Hormonal therapy of prostate cancer.
    Labrie F.
    Prog Brain Res; 2010 Mar; 182():321-41. PubMed ID: 20541672
    [Abstract] [Full Text] [Related]

  • 4. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M.
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [Abstract] [Full Text] [Related]

  • 5. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 7. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M, Lacombe L, Fradet Y.
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [Abstract] [Full Text] [Related]

  • 8. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 9. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 10. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 11. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 13. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.
    N Engl J Med; 2009 Jun 11; 360(24):2516-27. PubMed ID: 19516032
    [Abstract] [Full Text] [Related]

  • 14. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 11; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 15. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N.
    Exp Oncol; 2004 Sep 11; 26(3):185-91. PubMed ID: 15494685
    [Abstract] [Full Text] [Related]

  • 16. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM, Chertin B, Lindenberg T, Farkas A.
    N Engl J Med; 1999 May 06; 340(18):1439. PubMed ID: 10328706
    [No Abstract] [Full Text] [Related]

  • 17. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.
    Urol Int; 2006 May 06; 77(2):135-8. PubMed ID: 16888418
    [Abstract] [Full Text] [Related]

  • 18. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
    Morote J, Planas J, Salvador C, Raventós CX, Catalán R, Reventós J.
    BJU Int; 2009 Feb 06; 103(3):332-5; discussion 335. PubMed ID: 19007366
    [Abstract] [Full Text] [Related]

  • 19. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
    Kirby RS.
    Br J Clin Pract; 1996 Feb 06; 50(5):287. PubMed ID: 8794610
    [No Abstract] [Full Text] [Related]

  • 20. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ, Oh WK.
    Urology; 2006 May 06; 67(5):1084.e15-7. PubMed ID: 16698377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.